Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + durvalumab + platinum + etoposide
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination regimen is a four-drug therapy being evaluated as a first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). It consists of anlotinib, an oral multi-target tyrosine kinase inhibitor (TKI) that targets VEGFR, FGFR, PDGFR, and c-Kit; durvalumab (Imfinzi), a monoclonal antibody that blocks the PD-L1/PD-1 pathway to enhance anti-tumor immune responses; and standard chemotherapy comprising a platinum agent (cisplatin or carboplatin) and etoposide, a topoisomerase II inhibitor. The regimen is currently being studied in a Phase II clinical trial at Henan Cancer Hospital to leverage the synergistic effects of anti-angiogenesis, immunotherapy, and chemotherapy in improving outcomes for patients with aggressive ES-SCLC.
- Other names
- Anlotinib Plus Durvalumab-Platinum-EtoposideDurvalumab + Anlotinib + Chemotherapy
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on anlotinib + durvalumab + platinum + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + durvalumab + platinum + etoposide.